496 related articles for article (PubMed ID: 19545378)
21. Phenotypic and genotypic overlap between mosaic NF2 and schwannomatosis in patients with multiple non-intradermal schwannomas.
Kehrer-Sawatzki H; Kluwe L; Friedrich RE; Summerer A; Schäfer E; Wahlländer U; Matthies C; Gugel I; Farschtschi S; Hagel C; Cooper DN; Mautner VF
Hum Genet; 2018 Jul; 137(6-7):543-552. PubMed ID: 30006736
[TBL] [Abstract][Full Text] [Related]
22. Neurofibromatosis Type 2.
Ardern-Holmes S; Fisher G; North K
J Child Neurol; 2017 Jan; 32(1):9-22. PubMed ID: 27655473
[TBL] [Abstract][Full Text] [Related]
23. Germ-line mutations in the neurofibromatosis 2 gene: correlations with disease severity and retinal abnormalities.
Parry DM; MacCollin MM; Kaiser-Kupfer MI; Pulaski K; Nicholson HS; Bolesta M; Eldridge R; Gusella JF
Am J Hum Genet; 1996 Sep; 59(3):529-39. PubMed ID: 8751853
[TBL] [Abstract][Full Text] [Related]
24. Early Genetic Diagnosis of Neurofibromatosis Type 2 From Skin Plaque Plexiform Schwannomas in Childhood.
Castellanos E; Plana A; Carrato C; Carrió M; Rosas I; Amilibia E; Roca-Ribas F; Hostalot C; Castillo A; Ros A; Quer A; Becerra JL; Salvador H; Lázaro C; Blanco I; Serra E; Bielsa I;
JAMA Dermatol; 2018 Mar; 154(3):341-346. PubMed ID: 29322178
[TBL] [Abstract][Full Text] [Related]
25. [Neurofibromatosis type 2].
Pérez-Grau M; Miró N; Prades J; Vergés J; Lareo S; Roca-Ribas F
Acta Otorrinolaringol Esp; 2010; 61(4):306-11. PubMed ID: 20138250
[TBL] [Abstract][Full Text] [Related]
26. The neurofibromatoses. Part 2: NF2 and schwannomatosis.
Lu-Emerson C; Plotkin SR
Rev Neurol Dis; 2009; 6(3):E81-6. PubMed ID: 19898272
[TBL] [Abstract][Full Text] [Related]
27. Mutations and allelic loss of the NF2 gene in neurofibromatosis 2-associated skin tumors.
Kluwe L; Friedrich RE; Hagel C; Lindenau M; Mautner VF
J Invest Dermatol; 2000 May; 114(5):1017-21. PubMed ID: 10771486
[TBL] [Abstract][Full Text] [Related]
28. Neurofibromatosis type 2 in the elderly population: clinical and molecular features.
Goutagny S; Bah AB; Parfait B; Sterkers O; Kalamarides M
Am J Med Genet A; 2013 Apr; 161A(4):667-70. PubMed ID: 23322716
[TBL] [Abstract][Full Text] [Related]
29. Neurofibromatosis type 2.
Slattery WH
Otolaryngol Clin North Am; 2015 Jun; 48(3):443-60. PubMed ID: 26043141
[TBL] [Abstract][Full Text] [Related]
30. Advances in the treatment of neurofibromatosis-associated tumours.
Lin AL; Gutmann DH
Nat Rev Clin Oncol; 2013 Nov; 10(11):616-24. PubMed ID: 23939548
[TBL] [Abstract][Full Text] [Related]
31. An update on the CNS manifestations of neurofibromatosis type 2.
Coy S; Rashid R; Stemmer-Rachamimov A; Santagata S
Acta Neuropathol; 2020 Apr; 139(4):643-665. PubMed ID: 31161239
[TBL] [Abstract][Full Text] [Related]
32. Long-term natural history of neurofibromatosis Type 2-associated intracranial tumors.
Dirks MS; Butman JA; Kim HJ; Wu T; Morgan K; Tran AP; Lonser RR; Asthagiri AR
J Neurosurg; 2012 Jul; 117(1):109-17. PubMed ID: 22503123
[TBL] [Abstract][Full Text] [Related]
33. Somatic NF2 gene mutations in familial and non-familial vestibular schwannoma.
Irving RM; Moffat DA; Hardy DG; Barton DE; Xuereb JH; Maher ER
Hum Mol Genet; 1994 Feb; 3(2):347-50. PubMed ID: 8004107
[TBL] [Abstract][Full Text] [Related]
34. Frequent NF2 gene transcript mutations in sporadic meningiomas and vestibular schwannomas.
Lekanne Deprez RH; Bianchi AB; Groen NA; Seizinger BR; Hagemeijer A; van Drunen E; Bootsma D; Koper JW; Avezaat CJ; Kley N
Am J Hum Genet; 1994 Jun; 54(6):1022-9. PubMed ID: 7911002
[TBL] [Abstract][Full Text] [Related]
35. Bilateral vestibular schwannomas in older patients: NF2 or chance?
Evans DG; Freeman S; Gokhale C; Wallace A; Lloyd SK; Axon P; Ward CL; Rutherford S; King A; Huson SM; Ramsden RT;
J Med Genet; 2015 Jun; 52(6):422-4. PubMed ID: 25725045
[TBL] [Abstract][Full Text] [Related]
36. Intracranial meningiomas and neurofibromatosis type 2.
Aboukais R; Zairi F; Baroncini M; Bonne NX; Schapira S; Vincent C; Lejeune JP
Acta Neurochir (Wien); 2013 Jun; 155(6):997-1001; discussion 1001. PubMed ID: 23558725
[TBL] [Abstract][Full Text] [Related]
37. Neurofibromatosis type 2.
Asthagiri AR; Parry DM; Butman JA; Kim HJ; Tsilou ET; Zhuang Z; Lonser RR
Lancet; 2009 Jun; 373(9679):1974-86. PubMed ID: 19476995
[TBL] [Abstract][Full Text] [Related]
38. Genetic Severity Score predicts clinical phenotype in NF2.
Halliday D; Emmanouil B; Pretorius P; MacKeith S; Painter S; Tomkins H; Evans DG; Parry A
J Med Genet; 2017 Oct; 54(10):657-664. PubMed ID: 28848060
[TBL] [Abstract][Full Text] [Related]
39. CNS Young Investigator Award Lecture: molecular analysis of the neurofibromatosis 2 tumor suppressor.
MacCollin M
Brain Dev; 1995; 17(4):231-8. PubMed ID: 7503383
[TBL] [Abstract][Full Text] [Related]
40. Allelic expression of the NF2 gene in neurofibromatosis 2 and schwannomatosis.
Jacoby LB; MacCollin M; Parry DM; Kluwe L; Lynch J; Jones D; Gusella JF
Neurogenetics; 1999 Apr; 2(2):101-8. PubMed ID: 10369886
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
